Basic Research Support for the CCR

CCR的基础研究支持

• 批准号: 7970004
• 负责人: Robert Wiltrout
• 金额: $ 105.07万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7970004
• 关键词: Acquired Immunodeficiency Syndrome; Algorithms; Animal Technicians; Apoptotic; Area; Arts; Autoimmune Diseases; Basic Science; Biochemical; Biological Assay; Breast; CD4 Positive T Lymphocytes; Cancer Research Project; Cell physiology; Cell surface; Cells; Chemistry; Chronic; Clinical; Communicable Diseases; Comparative Carcinogenesis; Complex; Contrast Media; Development; Disease; Drug Delivery Systems; Drug resistance; Embryonic Development; Epigenetic Process; Epithelial; Event; Genetic; Genomics; Glioma; Glycobiology; Growth; HIV; HLA Antigens; Hematopoiesis; Human; Human Resources; Human T-Cell Leukemia Viruses; Immune response; Immunogenetics; Immunologic Deficiency Syndromes; Immunotherapy; Inflammation; Information Technology; Interleukins; Laboratories; Laboratory Animals; Laboratory Research; MHC Class II Genes; Malignant Neoplasms; Medical Imaging; Microarray Analysis; Mission; Molecular; Molecular Biology; Molecular Target; Mus; NCI Center for Cancer Research; National Cancer Institute; Natural Killer Cells; Natural Products Chemistry; Neoplasm Metastasis; Neoplasms; Nitric Oxide; Pathogenesis; Pathway interactions; Pattern; Play; Predisposition; Prevention therapy; Prostate; Protein Chemistry; Proteins; Qualifying; Reaction; Regulation; Renal Cell Carcinoma; Renal carcinoma; Research; Research Support; Resistance; Reverse Transcription; Ribosomes; Role; Scientist; Screening procedure; Signal Pathway; Signal Transduction; Stem cells; Stress; Structure; Study Section; Susceptibility Gene; Technical Expertise; Urologic Oncology; Vaccines; Viral Antigens; Viral Proteins; Virus; anticancer research; base; cancer diagnosis; cancer genetics; cancer prevention; cancer stem cell; cancer therapy; carcinogenesis; cell growth; cellular imaging; design; epidemiology study; genetic epidemiology; glycosyltransferase; group support; in vivo; metabolic abnormality assessment; multidisciplinary; nanobiology; novel; programs; protein protein interaction; ras Proteins; receptor; self-renewal; stem cell biology; structural biology; tumorigenesis; vaccine development

The Basic Research Program provides scientific and technical expertise to the Center for Cancer Research (CCR) in areas ranging from cancer and human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), to the basic cellular processes underlying cancer, infectious diseases, and autoimmune disorders. Research topics supported by the Basic Research Program include: -Investigating ways in which novel, molecularly targeted cancer therapies can be used in combination with immunotherapy (Molecular Immunotherapy Section, Cancer and Inflammation Program). -Understanding the genetic basis for resistance or susceptibility to disease conferred by human leukocyte antigen (HLA) class I and class II genes and the role of natural killer (NK) cells in the innate immune response (HLA Immunogenetics Section, Cancer and Inflammation Program). -Characterizing the receptors that activate natural killer (NK) cells and the innate immune response (Cytotoxic Cell Studies Group, Cancer and Inflammation Program). -Examining the association of chronic inflammation with epithelial carcinogenesis (Interleukin In Vivo Studies Section, Cancer and Inflammation Program). -Defining the receptor complex of CD4+ cells, a primary target of human T-cell leukemia virus type I (HTLV Section, Cancer and Inflammation Program). -Identifying and defining the molecular events that regulate lineage commitment and terminal differentiation of hemotopoietic stem cells (Hematopoiesis and Stem Cell Biology Section, Laboratory of Cancer Prevention). -Defining the cell surface markers, metastasis ability, and pathways for growth and self-renewal, of cancer stem cells from prostate, breast, glioma, and renal cell carcinomas (Cancer Stem Cell Section, Laboratory of Cancer Prevention). -Studying the role that epigenetic regulation plays in cellular differentiation, embryonic development, and tumorigenesis (Epigenetics Section, Laboratory of Cancer Prevention). -Understanding the structure and function of glycosyltransferases and developing novel glycosyltransferases for targeted drug delivery and contrast agents for medical imaging (Structural Glycobiology Section, CCR Nanobiology Program). -Developing highly efficient, state-of-the-art algorithms to discover the structural patterns of proteins and predict molecular associations (i.e., protein-protein interactions) in support of nanodesign for cancer diagnosis, therapy, and prevention (Computational Structural Biology Group, CCR Nanobiology Program). -Support in bioassay development and screening, natural products chemistry, protein chemistry, molecular biology, and high-content cellular imaging to facilitate multidisciplinary, molecular targets discovery research (Molecular Targets Laboratory). -Basic and applied chemistry support for studies characterizing the reactions of the bioregulatory agent nitric oxide (NO) with organic compounds (Chemistry Section, Laboratory of Comparative Carcinogenesis). -Microarray analysis aimed at determining the role of K-ras protein in controlling cell growth and differentiation (Cellular Pathogenesis Section, Laboratory of Comparative Carcinogenesis). -Characterizing the inductive signaling pathways involved in metanephric blastemal cell specification/patterning to help define potential targets of carcinogenesis (Differentiation and Neoplasia Section, Laboratory of Comparative Carcinogenesis). -Studying the metabolic modulation of proliferative, apoptotic, and stress-related signaling in carcinogenesis and cancer susceptibility (Cancer Susceptibility Section, Laboratory of Comparative Carcinogenesis). -Developing new molecular approaches for genetic epidemiology studies (Genetic Epidemiology Section, Laboratory of Genomic Diversity). -Design and development of genetic, biochemical, and structural studies of medically important viral proteins (Reverse Transcription and Molecular Biology Group). -Support for studies focusing on retroviral vaccine development, immune response to viral antigens, and the role of structural RNAs and proteins in the function of ribosomes (Reverse Transcription and Molecular Biology Group). -Discovery and characterization of renal carcinoma susceptibility genes (Urologic Oncology Research Group, Urologic Oncology Branch).

基础研究计划为癌症研究中心（CCR）提供了科学和技术专长，从癌症和人类免疫缺陷病毒（HIV）/获得性免疫缺陷综合征（AIDS）到基本的细胞过程，传染病，感染性疾病和自身免疫性疾病的基本细胞过程。基础研究计划支持的研究主题包括： - 对新型分子靶向癌症疗法的研究方式与免疫疗法结合使用（分子免疫疗法部分，癌症和炎症计划）。 - 理解人类白细胞抗原（HLA）I类和II类基因赋予的抵抗或易感性的遗传基础，以及自然杀伤（NK）细胞在先天免疫反应中的作用（HLA免疫遗传学部分，癌症和炎症计划）。 - 激活自然杀手（NK）细胞和先天免疫反应的受体（细胞毒性细胞研究组，癌症和炎症计划）。 - 研究慢性炎症与上皮癌发生的关联（体内研究部分，癌症和炎症计划）。 - 定义CD4+细胞的受体复合物，CD4+细胞是人类T细胞白血病病毒I型的主要靶标（HTLV部分，癌症和炎症计划）。 - 识别并定义了调节血清干细胞谱系承诺和终末分化的分子事件（造血和干细胞生物学部分，预防癌症实验室）。 - 定义细胞表面标记，转移能力以及生长和自我更新的途径，来自前列腺，乳腺癌，神经胶质瘤和肾细胞癌（癌症干细胞部分，预防癌症预防实验室）的癌症干细胞。 - 研究表观遗传调节在细胞分化，胚胎发育和肿瘤发生中起作用的作用（表观遗传学部分，癌症预防实验室）。 - 理解糖基转移酶的结构和功能，并开发用于靶向药物递送的新型糖基转移酶和用于医学成像的对比剂（结构性糖生物学部分，CCR纳米生物学计划）。 - 开发高效，最先进的算法，以发现蛋白质的结构模式，并预测分子关联（即蛋白质 - 蛋白质相互作用），以支持纳米设计用于癌症诊断，治疗和预防（计算结构生物学组，CCR纳米生物学计划）。 - 在生物测定开发和筛选，天然产物化学，蛋白质化学，分子生物学和高含量细胞成像中的支持，以促进跨学科的分子靶标发现研究研究（分子靶标实验室）。 - 基本和应用化学支持，以表征生物调节剂一氧化氮（NO）与有机化合物的反应的研究（化学部分，比较癌变实验室）。 - 微阵列分析旨在确定K-RAS蛋白在控制细胞生长和分化中的作用（细胞发病机理部分，比较癌变实验室）。 - 将属于跨跨膜细胞规范/模式的电感信号通路特征，以帮助定义癌变的潜在靶标（分化和肿瘤部分，比较癌变实验室）。 - 研究癌变和癌症易感性中增生性，凋亡和应激相关信号的代谢调节（癌症易感性部分，比较癌变实验室）。 - 开发遗传流行病学研究的新分子方法（遗传流行病学部分，基因组多样性实验室）。 - 设计和发展医学上重要的病毒蛋白（逆转录和分子生物学组）的遗传，生化和结构研究。 - 研究重点是逆转录病毒疫苗发育，对病毒抗原的免疫反应以及结构RNA和蛋白质在核糖体功能（逆转录和分子生物学组）中的作用。 - 肾癌易感基因（泌尿科肿瘤研究小组，泌尿外科肿瘤学分支）的发现和表征。